Royalty Pharma PLC Form 4 insider transactions

Royalty Pharma plc's CEO, Pablo G. Legorreta, reported a future acquisition of Class A Ordinary Shares from an equity award settlement and a disposition of convertible derivative interests.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, increased his beneficial ownership of Class A Ordinary Shares and convertible LP interests.

Royalty Pharma plc's EVP, Investments & CLO, George W. Lloyd, acquired 3,696 Class A Ordinary Shares through the settlement of equity performance awards and was granted additional derivative interests.

Royalty Pharma plc's EVP & Vice Chairman, Christopher Hite, acquired 3,696 Class A Ordinary Shares as part of an equity award settlement.

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, acquired 2,772 Class A Ordinary Shares through an equity performance award settlement.

Royalty Pharma plc Director Elizabeth H. Weatherman was granted 8,558 Class A Ordinary Shares through restricted stock units as part of the company's independent director equity incentive plan.

Royalty Pharma plc Director Carole Ho is set to receive 8,558 Class A Ordinary Shares in restricted stock units as part of her compensation, vesting in 2026.

Royalty Pharma plc Director Henry A. Fernandez acquired 1,064 Class A Ordinary Shares valued at approximately $37,500 as part of his quarterly retainer payment under the company's equity incentive plan.

Royalty Pharma plc Director Bonnie L. Bassler acquired 1,064 Class A Ordinary Shares on June 30, 2025, as part of her compensation under the company's equity incentive plan.

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, reports the acquisition of Class E ordinary shares through an indirect transaction.

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, reports an indirect acquisition of Class E ordinary shares through Royalty Pharma Holdings Ltd.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reports the indirect acquisition of Class E ordinary shares in Royalty Pharma Holdings Ltd pursuant to a Membership Interests Purchase Agreement.

George W. Lloyd, EVP of Investments & CLO at Royalty Pharma plc, reports an indirect acquisition of 1,944,471 Class E ordinary shares through Royalty Pharma Holdings Ltd.

CEO and Chairman of the Board of Royalty Pharma, Pablo G. Legorreta, reports the transfer of Class A Ordinary Shares and acquisition of Class E Ordinary Shares and options.

Catherine Engelbert, a director at Royalty Pharma plc, was granted 7,614 Class A Ordinary Shares on May 13, 2025, as part of the company's 2020 Independent Director Equity Incentive Plan.

Director Gregory Norden of Royalty Pharma plc reports acquisition of 7,614 Class A Ordinary Shares through a restricted stock unit award.

Director Ted W. Love of Royalty Pharma plc reports acquisition of 7,614 Class A Ordinary Shares through a restricted stock unit award.

Director David C. Hodgson receives 7,614 Class A Ordinary Shares of Royalty Pharma plc through a restricted stock unit award.

Director Henry A. Fernandez reports acquisition of Royalty Pharma plc Class A Ordinary Shares through restricted stock units.

Director Errol B. DeSouza receives 7,614 Class A Ordinary Shares of Royalty Pharma plc as a restricted stock unit award.

Director Vlad Coric of Royalty Pharma plc reports acquisition of Class A Ordinary Shares through a restricted stock unit award.

Bonnie L. Bassler, a director at Royalty Pharma plc, received an award of 7,614 Class A Ordinary Shares on May 13, 2025.

CEO Pablo Legorreta reports an exempt gift of Class B ordinary shares from his spouse and a transfer of Class B shares to PL RPH AIV, LLC, a company he solely owns.

Pablo G. Legorreta, CEO and Chairman of the Board of Royalty Pharma plc, reported the acquisition of 288,352 Class A Ordinary Shares on May 8, 2025, alongside adjustments to his indirect beneficial ownership.

George W. Lloyd, EVP of Investments & CLO at Royalty Pharma plc, acquired 48,646 Class A Ordinary Shares through the settlement of Equity Performance Awards on May 8, 2025.

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, reports the acquisition of shares through equity performance awards and the disposal of shares.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reports the acquisition of 48,646 Class A Ordinary Shares through the settlement of Equity Performance Awards.

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, reports acquiring 36,484 Class A Ordinary Shares through the settlement of Equity Performance Awards.

Director Vlad Coric received 3,184 Class A Ordinary Shares of Royalty Pharma plc as a restricted stock unit award.

Director Bonnie L. Bassler acquired 1,141 Class A Ordinary Shares of Royalty Pharma plc in lieu of a quarterly retainer payment.